During HIV-1 infection, antibodies are generated against the region of the viral gp120 envelope glycoprotein that binds CD4, the primary receptor for HIV-1. Among these antibodies, VRC01 achieves broad neutralization of diverse viral strains. Here we determine the crystal structure of VRC01 in complex with an HIV-1 gp120 core. VRC01 partially mimics CD4 interaction with gp120. A shift from the CD4-defined orientation, however, focuses VRC01 onto the vulnerable site of initial CD4 attachment, allowing it to overcome the glycan and conformational masking that diminishes the neutralization potency of most CD4-binding-site antibodies. To achieve this recognition, VRC01 contacts gp120 mainly through Vgene-derived regions substantially altered from their genomic precursors. Partial receptor mimicry and extensive affinity maturation thus facilitate neutralization of HIV-1 by natural human antibodies.
Successful vaccine development often takes advantage of clues from humoral responses elicited by natural infection. For HIV-1, neutralizing antibody responses elicited within the first year or two of infection are generally strain-specific (1), and thus provide poor leads for vaccine development [reviewed in (2) ]. A few monoclonal antibodies from HIV-1 infected individuals, however, are broadly neutralizing, and an effort has been made to facilitate vaccine design by defining their structures (3) (4) .
The well-studied broadly neutralizing anti-HIV-1 antibodies, 2G12, 2F5, 4E10, and b12, have unusual characteristics that have posed barriers to eliciting similar antibodies in humans (5) . Thus, in addition to having broad capacity for neutralization, an appropriate antibody should be present in high enough titers in humans to suggest that such antibodies can be elicited in useful concentrations. We and others have screened cohorts of sera from infected individuals to find broadly neutralizing responses that are detectable in a substantial percentage of subjects (6) (7) (8) (9) (10) . One serum response that satisfies these criteria has been mapped to the site on HIV-1 gp120 envelope (Env) glycoprotein that binds to the CD4 receptor (8) .
While potentially accessible, the CD4-binding site is protected from humoral recognition by glycan and conformational masking (11) . The identification of monoclonal antibodies against this site is described in a companion manuscript (12). In brief, we created resurfaced, conformationally stabilized probes, with antigenic specificity for the initial site of CD4 attachment on gp120 (22). This site, a conformationally invariant subset of the CD4-binding surface, is vulnerable to antibody-mediated neutralization (22), and we used probes specific for this site to identify antibodies that neutralize most viruses (12) . Here, we analyze the crystal structure for one of these antibodies, VRC01, in complex with an HIV-1 gp120 core. We decipher the basis of VRC01 neutralization, identify mechanisms of natural resistance, show how VRC01 minimizes such resistance, examine potential barriers to elicitation, and define the role of affinity maturation in gp120 recognition.
Similarities of Env recognition by CD4 and VRC01 antibody. To gain a structural understanding of VRC01 neutralization, we crystallized the antigen-binding fragment (Fab) of VRC01 in complex with an HIV-1 gp120 from the clade A/E recombinant 93TH057 (13). The crystallized gp120 consisted of its inner domain-outer domain core, with truncations in the variable loops V1/V2 and V3 as well as the N-and C-termini, regions known to extend away from the main body of the gp120 envelope glycoprotein (14). Diffraction to 2.9 Å resolution was obtained from orthorhombic crystals, which contained four copies of the VRC01-gp120 complex per asymmetric unit, and the structure was solved by molecular replacement and refined to an R-value of 19.7% (R free of 25.6%) ( Fig. 1 For CD4, the CDR2-like region forms antiparallel, intermolecular hydrogen-bonds with residues 365-368 gp120 of the CD4-binding loop of gp120 (18) (Fig. 2B) ; with VRC01, one hydrogen-bond is observed between the carbonyl of Gly54 VRC01 and the backbone nitrogen of Asp368 gp120 . This hydrogen-bond occurs at the loop tip, an extra residue relative to CD4 is inserted in the strand, and the rest of the potential hydrogen bonds are of poor geometry or distance (Fig. 2C  and table S4 ). Other similarities and differences with CD4 are found: of the two dominant CD4 residues (Phe43 CD4 and Arg59 CD4 ) involved in interaction with gp120, VRC01 mimics the arginine interaction, but not the phenylalanine one (Fig. 2B, C) . Finally, significant correlation is observed between gp120 residues involved in binding VRC01 and CD4 ( fig. S1 ).
Superposition of the gp120 core in its VRC01-bound form with gp120s in other crystalline lattices and bound by other ligands indicates a CD4-bound conformation (PDB ID 3JWD) (14) to be most closely related in structure, with a Cα-root-mean-square deviation of 1.03 Å (table S5) . Such superposition of gp120s from CD4-bound and VRC01-bound conformations brings the N-terminal domain of CD4 and the heavy chain-variable domain of VRC01 into close alignment (Fig. 2) , with 73% of the CD4 N-terminal domain volume overlapping with VRC01 (19). This domain overlap is much higher than observed with the heavy chains of other CD4-binding site antibodies, such as b12, b13 or F105 (table S6) . However, when the VRC01 heavy chain is superimposedbased on conserved framework and cysteine residues -on CD4 in the CD4-gp120 complex, clashes are found between gp120 and the entire top third of the VRC01 variable light chain (Fig. 2D) (20) . In its complex with gp120, VRC01 rotates 43° relative to the CD4-defined orientation, and translates 6-Å away from the bridging sheet, to a clash-free orientation that mimics many of the interactions of CD4 with gp120, though with considerable variation. Analysis of electrostatics shows that the interaction surfaces of VRC01 and CD4 are both quite basic, though the residues types of contacting amino acids are distinct ( fig. S2 ). Thus, while VRC01 mimics CD4 binding to some extent, considerable differences are observed.
Structural basis of VRC01 breadth and potency. When CD4 is placed into an immunoglobulin context by fusing its two N-terminal domains to a dimeric immunoglobulin constant region, it achieves reasonable neutralization. VRC01, however, neutralizes better (Fig. 3A) (12) . To understand the structural basis for the exceptional breadth and potency of VRC01, we analyzed its interactive surface with gp120. VRC01 focuses its binding onto the conformationally invariant outer domain, which accounts for 87% of the contact-surface area of VRC01 (table S7). The 13% of the contacts made with flexible inner domain and bridging sheet are non-contiguous and are not critical for binding. In contrast, CD4 makes 33% of its contacts with the bridging sheet, and many of these interactions are essential (18). The reduction in inner domain and bridging sheet interactions by VRC01 is accomplished primarily by a 6-Å translation relative to CD4, away from these regions; critical contacts such as made by Phe43 CD4 to the nexus of the bridging sheetouter domain are not found in VRC01, while those to the outer domain (e.g. Arg59 CD4 ) are mimicked by VRC01.
To determine the affinity of VRC01 for gp120 in CD4-bound and non-CD4-bound conformations, we used surfaceplasmon resonance spectroscopy to measure the affinity of VRC01 and other gp120-reactive antibodies and ligands to two gp120s: a β4-deletion developed by Harrison and colleagues that is restrained from assuming the CD4-bound conformation (21) or a disulfide-stabilized gp120 core, largely fixed in the CD4-bound conformation in the absence of CD4 itself (18) (Fig. 3B and fig. S3 ). VRC01 showed high affinity to both CD4-bound and non-CD4-bound conformations, a property shared by the broadly neutralizing b12 antibody (21-22). By contrast, antibodies F105 and 17b as well as soluble CD4 showed strong preference for either one, but not both, of the conformations.
To assess the binding of VRC01 in the context of the functional viral spike, we examined its ability to neutralize variants of HIV-1 with gp120 changes that affect the ability to assume the CD4-bound state. Two of these mutations, His66Ala gp120 and Trp69Leu gp120 , are less sensitive (23), while a third, Ser375Trp gp120 , is more sensitive to neutralization by CD4 (23-24). VRC01 neutralized all three of these variant HIV-1 viruses with similar potency (Fig. 3C ), suggesting that VRC01 recognizes both CD4-bound and non-CD4-bound conformations of the viral spike. This recognition diversity allows VRC01 to avoid the conformational masking that hinders most CD4-binding-site ligands (25) and to neutralize HIV-1 potently (26).
Precise targeting by VRC01. Prior analysis of effective and ineffective CD4-binding-site antibodies suggested that precise targeting to the vulnerable site of initial CD4 attachment is required to block viral entry (11, 27) . This site represents the outer domain-contact site for CD4 (22). Analysis of the VRC01 interaction with gp120 shows that it covers 98% of this site ( Natural resistance to antibody VRC01. In addition to conformational masking and glycan shielding, HIV-1 resists neutralization by antigenic variation. In a companion manuscript, we show that of the 190 circulating HIV-1 isolates tested for sensitivity to VRC01, 173 were neutralized and 17 were resistant (12). To understand the basis of this natural resistance to VRC01, we analyzed all 17 resistant isolates by threading their sequences onto the gp120 structure ( fig. S5 ). Variation was observed in the V5 region in resistant isolates, and this variation -along with alterations in gp120 loop D -appeared to be the source of most natural resistance to VRC01 (Fig. 4C , figs. S5, S6).
Because substantial variation exists in V5, structural differences in this region might be expected to result in greater than 10% resistance. The lower observed frequency of resistance suggests that VRC01 employs a recognition mechanism that allows for binding despite V5 variation. Examination of VRC01 interaction with V5 shows that VRC01 recognition of V5 is considerably different from that of CD4 ( fig. S7) , with Arg61 VRC01 in the CDR H2 penetrating into the cavity formed by the V5 and β24-strands of gp120 ( fig. S8 ). Most importantly, the V5 loop fits into the gap between heavy and light chains; thus by contacting only the more conserved residues at the loop base, VRC01 can tolerate variation in the tip of the V5 loop (Fig. 4D) .
Unusual VRC01 features and contribution to recognition. We examined the structure of VRC01 for special features that might be required for its function. A number of unusual features were apparent, including a high degree of affinity maturation, an extra disulfide bond, a site for N-linked glycosylation, a 2-amino acid deletion in the light chain, and an extensively matured binding interface between VRC01 and gp120 ( Fig. 5 and fig. S9 ). We assessed the frequency with which these features were found in HIV-1 Env-reactive antibodies (SOM Appendix) or in human antibody-antigen complexes ( fig. S10 and tables S8, S9) , and measured the effect of genomic reversion of these features on affinity for gp120 and neutralization of virus (Fig. 5A-D , table S10).
Higher levels of affinity maturation have been reported for HIV-1 reactive antibodies in general (29), and markedly higher levels for broadly neutralizing ones (30). These maturation levels could be a by-product of the persistent nature of HIV-1 infection, and may not represent a functional requirement. Removal of the N-linked glycosylation or the extra disulfide bond, which connects CDR H1 and H3 regions of the heavy chain, had little effect on binding or neutralization (Figs. 5A, 5B and table S10). Insertion of 2-amino acids to revert the light chain deletion had moderate effects, which were larger for an Ala-Ala insertion (50-fold decrease in K D ) versus a Ser-Tyr insertion (5-fold decrease in K D ), which mimics the genomic sequence ( Fig. 5C and table S10). Finally reversion of the interface was examined with either single-, 4-, 7-or 12-mutant reversions. For the singlemutant reversions of the interface to the genomic antibody sequence, all 12 mutations had minor effects (most with less than 2-fold effect on K D, with the largest effect for a Gly54Ser change with a K D of 20.2 nM) (table S10). Larger effects were observed with multiple (4, 7 or 12) changes, and these reduced the measured K D by 5-30 fold and EC 50 s or neutralization percentages by 10-100 fold ( Fig. 5D and table S10). Thus, while VRC01 has a number of unusual features, no single alteration to genomic sequence reduced binding or neutralization by more than 10-fold.
Elicitation of VRC01-like antibodies. The probability for elicitation of a particular antibody is a function of each of the three major steps in B cell maturation: 1. Recombination to produce nascent antibody heavy and light chains from genomic V H -D-J and V κ/λ -J precursors; 2. Deletion of autoreactive antibodies; and 3. Maturation through hypermutation of the variable domains to enhance antigen affinity. For the recombination step, a lack of substantial CDR L3 and H3 contribution to the VRC01-gp120 interface (table S2) indicates that specific V κ/λ -J or V H (D)J-recombination is not required (31) (fig. S11 ). The majority of recognition occurs with elements encoded in single genomic elements or cassettes, suggesting that specific joints between them are not required. Within the V H cassette, a number of residues associated with the IGHV1-02*02 precursor of VRC01 interact with gp120; many of these are conserved in related genomic V H s, some of which are of similar genetic distance from VRC01 ( fig. S12 ). These results suggest that appropriate genomic precursors for VRC01 are likely to occur at a reasonable frequency in the human antibody repertoire.
Recombination produces nascent B cell-presented antibodies that have reactivities against both self and nonself antigens. Those with auto-reactivity are removed through clonal deletion. With many of the broadly neutralizing anti-HIV-1 antibodies, such as 2G12 (glycan reactive) (32-33), 2F5 and 4E10 (membrane reactive) (34-35), this appears to be a major barrier to elicitation. While this remains to be characterized for genomic revertants and intermediates, no auto-reactivity has so far been observed with VRC01 (12).
The third step influencing the elicitation of VRC01-like antibodies is affinity maturation, a process involving hypermutation of variable domains combined with affinitybased selection that occurs during B cell maturation in germinal centers (36). In the case of VRC01, 41 residue alterations were observed from the genomic V H -gene and 25 alterations from the V Κ -gene (including a deletion of two residues) (fig. S13) (37). To investigate the effect of affinity maturation on HIV-1 gp120 recognition, we reverted the V Hand V Κ -regions of VRC01, either individually or together, to the sequences of their genomic precursors. We tested the affinity and neutralization of these reverted antibodies (Fig.  6A) , and combined these data with the genomic reversion data obtained while querying the unusual molecular features of VRC01 (previous section) (Fig. 6B) .
No antibodies containing genomic V H and V κ regions bound gp120 or neutralized virus (38). Binding affinity and neutralization showed significant correlations with the number of affinity-matured residues (p<0.0001). Interestingly, binding to stabilized gp120 did not correlate well with other types of gp120 or to neutralization (table S11), related in part to greater retention of binding to VRC01 variants with genomically reverted V κ regions. Extrapolation of the correlation to the putative genomic V-gene sequences predicted binding affinities of 0.6 μM K D for gp120 stabilized in the CD4-bound conformation and substantially weaker affinites for non-stabilized gp120s (Fig. 6B and fig. S14 ).
Notably, no single affinity maturation alteration appeared to affect affinity by more than 10-fold, suggesting that affinity maturation occurs in multiple small steps, which collectively enable tight binding to HIV-1 gp120. When the effects of VRC01 affinity maturation reversions are mapped to the structure of the VRC01-gp120 complex, they are broadly distributed throughout the VRC01 variable domains, rather than focused on the VRC01-gp120 interface. Noncontact residues therefore appear to influence the interface with gp120 through indirect protein-folding effects. Thus, for VRC01, the process of affinity maturation entails incremental changes of the nascent genomic precursors to obtain high affinity interaction with HIV-1 Env surface.
Receptor mimicry and affinity maturation. The possibility of antibodies using conserved sites of receptor recognition to neutralize viruses effectively has been pursued for several decades. The recessed canyon on rhinovirus that recognizes the unpaired terminal immunoglobulin domains of ICAM-1 highlights the steric role that a narrow canyon entrance may play in occluding bivalent antibody-combining regions (39) , although framework recognition can in some instances permit entry (40) . Partial solutions such as those presented by antibody b12 (neutralization of 40% of circulating isolates) (22) or by antibody HJ16 (neutralization of 30% of circulating isolates) (41), a recently identified CD4-binding-site antibody, may allow recognition of some HIV-1 isolates.
With VRC01, the potency and breadth of neutralization (over 90%) suggests a more general solution. It remains to be seen how difficult it will be to guide the elicitation of VRC01-like antibodies from genomic rearrangement, through affinity maturation, to broad and potent neutralization of HIV-1. Accumulating evidence suggests that the VRC01-defined mode of recognition is used by other antibodies (12). These findings suggest that VRC01 is not an isolated example, and likely provides a template for a general mode of recognition. The structure-function insights of VRC01 described here thus provide a foundation for rational vaccine design based not only on the particular mode of antibodyantigen interaction, but also on defined relationships between genomic antibody precursors, somatic hypermutation, and required recognition elements. , with a combined interaction surface of 123 Å 2 (tables S3 and S12). These four residues are likely contributed by the D segment (IGHD3-16*02), and none of them appears critical to VRC01 recognition, as changes are observed in two of these residues in the closely related broadly-neutralizing antibody VRC03, which was one of two antibodies we isolated along with VRC01 (12). Meanwhile, three residues are provided by the CDR L3, Tyr91 VRC01 , Glu96 VRC01 and Phe97 VRC01 , with a combined interaction surface of 190 Å 2 (tables S3 and S13). These three residues lie at the junction between V-and J-genes. They make important hydrophobic interactions with loop D of gp120, and two of them are conserved between VRC01 and VRC03. While it is difficult to know how precisely the CDR L3 needs to be aligned, with only three contact residues, variation at the V K -J gene junction should provide sufficient diversity for it to be represented in the repertoire. S13 ). In terms of the subset of HIV-1 Env-reactive antibodies that are broadly neutralizing (e.g. 2G12, 2F5, 4E10 and b12), antibodies b12 and 2G12 have 45 and 51 changes, respectively, relative to nearest genomic precursors in their V H -and J-segments of the heavy chain (30). 38. Similar significant reductions in affinity have been observed with reversion of other broadly neutralizing, anti-HIV-1 antibodies to putative genomic sequences (46-48); these observations have led to the suggestion that the dramatically reduced germline affinity for gp120 might hinder the initiation of affinity maturation of these antibodies (49) . That is, if the affinity for gp120 of the genomic precursor of a broadly neutralizing antibody were below the threshold required for the nascent B cell to mature, then maturation would either not occur or would need to occur in response to a different immunogen. This lack of guided initiation of the maturation process may provide an explanation for the absence of such broadly neutralizing antibodies in the first few years of infection. Conversely, the introduction of modified gp120s with affinity to genomic precursors and affinity maturation intermediates could provide a mechanism by which to elicit antibodies like VRC01. Polypeptides are shown in ribbon representation, with gp120 colored the same as in A and VRC01 depicted with heavy chain in dark yellow and light chain in dark gray. When the heavy chain of VRC01 is superimposed onto CD4 in the CD4-gp120 complex, the position assumed by the light chain evinces numerous clashes with gp120 (left). The VRC01-binding orientation (right) avoids clashes by adopting an orientation rotated by 43° and translated by 6-Å. Residues altered by affinity maturation are depicted with "balls" and contacts with HIV-1 gp120 are colored red. About half the contacts are altered during the maturation process. Analysis of human antibody-protein complexes in the protein-data bank shows this degree of contact surface alteration is rare; reversion of each of the contact site to genome has little effect (table S10), though in aggregate the effect on affinity is larger. Fig. 6 . Somatic maturation and VRC01 affinity. Hypermutation of the variable domain during B cell maturation allows for the evolution of high affinity antibodies. With VRC01 this enhancement to affinity occurs principally through the alteration of non-contact residues, which appear to reform the genomic contact surface from
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